null

Phospho-ATM-S1981 Rabbit Polyclonal Antibody (CABP0008)

SKU:
CABP0008
Product Type:
Antibody
Applications:
WB
Reactivity:
Human
Host Species:
Rabbit
Isotype:
IgG
Research Area:
Cell Cycle
  • Cell Cycle Antibodies 2 Anti-Phospho-ATM-S1981 Antibody CABP0008
  • Cell Cycle Antibodies 2 Anti-Phospho-ATM-S1981 Antibody CABP0008
  • Cell Cycle Antibodies 2 Anti-Phospho-ATM-S1981 Antibody CABP0008
  • Cell Cycle Antibodies 2 Anti-Phospho-ATM-S1981 Antibody CABP0008
€419
Frequently bought together:

Description

system_update_altDatasheetsystem_update_altMSDS

Phospho-ATM-S1981 Rabbit Polyclonal Antibody (CABP0008)

The Phospho-ATM (S1981) Polyclonal Antibody (CABP0008) is a crucial tool for researchers studying the ATM protein, a key player in DNA damage response pathways. This antibody, generated in rabbits, exhibits high specificity and sensitivity for detecting levels of phosphorylated ATM at serine 1981 in human samples. Validated for use in Western blot applications, it enables precise quantification and visualization of ATM activation in various cell types.ATM, a member of the PI3/PI4-kinase family, is known to phosphorylate numerous downstream targets involved in cell cycle regulation, DNA repair, and apoptosis. Phosphorylation of ATM at serine 1981 is a hallmark of its activation in response to double-strand DNA breaks, playing a crucial role in initiating DNA damage repair mechanisms.

Understanding the dynamics of ATM activation is essential for unraveling its intricate functions in maintaining genomic integrity and preventing the accumulation of mutations that can lead to cancer and other genetic diseases. By providing a reliable means to assess ATM phosphorylation status, the Phospho-ATM (S1981) Polyclonal Antibody (CABP0008) offers researchers a valuable tool for investigating the molecular mechanisms underlying DNA damage response pathways. Its application extends to fields such as cancer biology, radiation therapy, and drug development, where targeting ATM signaling holds promise for improving treatment outcomes and overcoming resistance to genotoxic therapies.